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Reactive oxygen speciesctional promoter of twomouse genes encoding components of themitochondrial
translational apparatus,mitoribosomal protein S12 (Mrps12) andmitochondrial seryl-tRNA ligase (Sarsm),was
shownpreviously to be dependent upon an array of four CCAAT boxes, interacting with the transcription factor
NF-Y. Here we report that the homologous human promoter is governed by a CCAAT box array acting in an
essentially similarmanner. Analysis of the transcriptional response of both the human andmouse promoters to
various mitochondrially acting toxins, including inhibitors of mitochondrial protein synthesis, and agents that
bring about uncoupling or respiratory chain inhibition, produced either of two distinct outcomes, depending
on the cell type and the conditions used. In mouse C2C12 myoblasts, human HEK293 cells or U2OS
osteosarcoma cells, plus HeLa cells at high drug doses or mouse 3T3 ﬁbroblasts subjected to prolonged drug
exposure, a dose-dependent, bidirectional suppression of transcription was observed. In 3T3 cells subjected
only to pre-treatment with the drugs, bidirectionalMrps12/Sarsm promoter activitywas strongly stimulated. A
similar, though weaker stimulation was observed at lower drug doses in HeLa cells. Reporter studies using
mutated variants of the mouse promoter construct indicated that the stimulation of promoter activity in
response tomitochondrial OXPHOS stress in 3T3 cells was independent of the CCAAT box array and of putative
binding sites for NRF-2, AP-1 and other transcription factors, whereas transcriptional downregulation under
prolonged mitochondrial stress was CCAAT box-dependent. Promoter stimulation was correlated with
mitochondrial ROS production, which may be a crucial component in its signalling.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionMitochondrial biogenesis is considered to be part of the programme
of cellular proliferation, as well as to respond to speciﬁc developmental,
physiological and stress-related signals. Most nuclear genes for
components of the mitochondrial oxidative phosphorylation (OXPHOS)
system, as well as the genes whose products play key roles in mtDNA
maintenance and expression, are governed by one or more promoter
elements interacting with globally active transcription factors linked to
cell proliferation, such asAP-1, NF-Yor CREB, or the factors designated as
‘nuclear respiratory factors’1 and2,NRF-1, NRF-2 [1–8]. Binding sites for
NRF-1 and NRF-2, originally proposed to deﬁne a speciﬁc mitochondrial
regulon, are also found in a wide range of other genes linked to cell
proliferation, although a more direct connection to mitochondrial
function remains the generally accepted hypothesis. The importance
of NF-Y in maintaining the OXPHOS systemwas recently demonstrated
by the rescue of a pathological cytochrome c oxidase assemblymutant in
the SURF1 gene in human ﬁbroblasts, via overexpression of the
components of the NF-Y complex [9]. The co-activator PGC-1α has
also been shown to play a key role inmodulating the activity of nuclear-ology, FI-33014 University of
551 7710.
l rights reserved.coded mitochondrial genes in response to physiological signals, and to
be involved in recruiting factors such as NRF-1, NRF-2 and the estrogen-
related receptor ERRα to the relevant promoters [4,8]. AP-1, CREB and
NRF-1 have also been reported to be involved in the sensing of
mitochondrial ROS signals induced by estrogen [10].
In yeast, many promoters for nuclear-coded mitochondrial genes
respond to mitochondrial OXPHOS stress via the so-called retrograde
pathway [11], which involves dedicated transcription factors which
regulate speciﬁc target genes in response to an as yet unidentiﬁed
molecular second messenger, for which the protein Rtg2p acts as a
sensor. The retrograde response pathway interacts with the mTOR
pathway, which signals growth shutdown under more general nutri-
tional stress, in particular under amino acid starvation [12]. In higher
eukaryotes such as mammals, although the mTOR pathway is well
characterized, themachinery equivalent to that of the yeast retrograde
response pathway has not been identiﬁed, although other transcrip-
tional response elements and factors appear to be involved in a super-
ﬁcially similar type of signalling [13]. It has been suggested that the
increased biological complexity of multicellular organisms is reﬂected
in a more complex programme of retrograde signalling, and that
different mitochondrial stresses might be interpreted differently, and
according to the cell type. Apart from the role of PGC-1α, as well as the
apparent involvement of calcium signalling in muscle and other cells
under mitochondrial OXPHOS stress [14,15], rather little is known of
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responses to mitochondrial dysfunction. A range of transcription
factors is induced by mtDNA depletion or uncoupling by FCCP in
human cells [15], including ATF, NFAT, C/EBPdelta and CREB, and CREB
activation has also been implicated in proliferation arrest induced by
mitochondrial dysfunction in various cell lines [16]. However, the exact
role each of these factors plays inmediating stress responses at the level
of transcription of nuclear OXPHOS genes remains to be documented.
In a previous study [7], using a dual reporter strategy in combination
withEMSAandChIP assays,we characterized thebidirectional promoter
of twomouse nuclear genes encoding components of themitochondrial
translational apparatus, mitoribosomal protein S12 (Mrps12) and
mitochondrial seryl-tRNA ligase (Sarsm). In addition to a binding site
for NRF-2, loss of which was shown to decrease transcription in both
directions by approximately 50% in 3T3 cells, we identiﬁed an array of
four CCAAT boxes interacting with the transcription factor NF-Y. These
were shown to be required for efﬁcient, bidirectional transcription, with
the terminal CCAAT boxes of the array playing key roles in enforcing
directionality towards the opposite end of the promoter. These studies
were all conducted in growing cells, raising the question of whether
these promoter elements are required purely for responses to
proliferative signals, or whether they could also play a role in regulating
mitochondrial biogenesis in response to speciﬁc physiological stresses
affecting mitochondria. The bidirectional organization of the Mrps12/
Sarsm promoter may present unusual requirements for such responses.
To address this issue we used the same bidirectional reporter
strategy to assess the activity of the Mrps12/Sarsm promoter under
mitochondrial stress conditions induced by a variety of drugs,
including mitochondrial protein synthesis inhibitors such as doxycy-
cline [17] and thiamphenicol [18,19], respiratory poisons and
uncouplers (rotenone, antimycin, FCCP), and treatments that induce
hypoxia or NO production. In order to compare the responses of
commonly used mouse and human cell lines, we ﬁrst characterized
the human MRPS12/SARSM promoter, using a similar dual reporter
strategy combined with EMSA, which revealed that the CCAAT box
array functions in essentially the same manner in human as in mouse.
We then studied the effects of mitochondrial OXPHOS stress on
promoter activity in different cell lines. The responses were drama-
tically different, depending on the cell lines and the conditions used.
Most cell lines of either species showed downregulation of promoter
activity, but two cell lines showed transcriptional stimulation, unless
drug treatment was prolonged or at a high level. Reporter assays using
mutated variants of the mouse promoter showed that stimulation of
transcription in 3T3 cells was independent of the CCAAT box array, as
well as of the putative binding sites in the promoter region for NRF-2,
AP-1 and other known transcription factors, whereas downregulation
of promoter activity under prolonged mitochondrial stress was CCAAT
box-dependent. Regulation of the Mrps12/Sarsm promoter under
conditions of mitochondrial OXPHOS stress would appear to involve at
least one novel factor and/or mechanism.
2. Materials and methods
2.1. Cells and cell-culture
Mouse NIH 3T3 and C2C12 cells and human HEK293, U2OS and
HeLa cells were cultured in DMEM (Cambrex) supplemented with 10%
fetal bovine serum, containing 50 U/ml penicillin (Cambrex) and
50 μg/ml streptomycin (Cambrex). All cells weremaintained at 37 °C in
5% CO2, and passaged every 2–3 days as required.
2.2. Oligonucleotides, plasmids and in vitro mutagenesis
The MRPS12/SARSM intergenic region was ampliﬁed from human
(HEK293 cell) genomic DNA using chimeric primers RPMS12F_1 and
HsarsmF_1 (see Supplementary Table 1). The PCR product was di-gested with NcoI and then cloned into the dual luciferase reporter
vector pFRL [7], also cut with NcoI, generating clones in both orien-
tations. To create a deletion series from the wild-type template, either
of the same terminal primers was used together with the deletion
primers indicated in Supplementary Table 1, with each product cloned
into the NcoI site of pFRL using a similar strategy as for the wild-type
promoter. To create point mutants of the dual reporter construct, a
two-round mutagenic PCR strategy was employed, using primers as
indicated in Supplementary Table 1. In each case the ﬁnal PCR product,
obtained using primers RPMS12F_1 and HsarsmF_1, was cloned into
theNcoI site of pFRL. Each constructwas veriﬁed by sequencing in both
directions. The mouse Mrps12/Sarsm intergenic region dual luciferase
reporter construct, point mutants thereof, plus the β-galactosidase
reporter construct, were as described previously [7].
2.3. DNA transfections and reporter assays
Cells grown to 80% conﬂuencewere transfected in 6-well plates, using
TransFectin Lipid Reagent (Bio-Rad) or FUGENE 6 (Roche, U2OS cells
only), according to the manufacturer's instructions, with either 0.25 μg
(HEK293 cells only) or 0.5 μg of DNA from each luciferase construct, plus
the same amount of DNA of the β-galactosidase control vector. After 24 h
ﬁreﬂy and Renilla luciferase activities were assayed in cell lysates using
the Dual Luciferase Reporter Assay System (Promega) and a BioORBIT
1254 luminova luminometer. Beta-galactosidase activitywas determined
in 50 μl aliquots of the same lysates by the addition of 50 μl ONPG solution
(2-nitrophenyl β-D-galactopyranoside) and 10 μl of 500 mM NaCl,
100 mM MgCl2, 100 mM β-mercaptoethanol, with incubation at 37 °C
for 1 h and measurement of A420. Luciferase activities were normalized
for transfection efﬁciency using β-galactosidase activity.
2.4. Drug treatments
FCCP (Sigma) dissolved in ethanol, antimycin (Sigma) plus rote-
none (Sigma) dissolved in ethanol, thiamphenicol (Sigma) dissolved
in DMSO or doxycycline (Sigma) dissolved in water, were added to
cells at the concentrations indicated in the ﬁgures for 12 h prior to
transfection, after which the medium was changed immediately
before transfection. For prolonged exposure, the drugs were
reintroduced to the culture medium 4 h after transfection. In trial
experiments it was determined that the solvents used (ethanol and
DMSO) had no effect on promoter activity. To induce a hypoxia
response, cells were treated with CoCl2 (dissolved in water) at
various concentrations (120 to 200 μM) commencing 5 h after
transfection. Arginine/citrulline treatments (0.5 mM or 1.5 mM of
each) were carried out for 12 h prior to transfection as for the other
drugs.
2.5. EMSA
EMSA, with or without supershifting, was carried out as previously
described [7], but using nuclear extracts from HEK293 cells.
2.6. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed as described previously [7], except that
HEK293 cells were used instead of 3T3 cells, and the PCR step used
human MRPS12/SARSM promoter-speciﬁc primers HsarsmF_1 and
RPMS12F_5 (Supplementary Table 1).
2.7. Mitochondrial ROS production
Mitochondrial ROS production was measured ﬂuorimetrically,
essentially as described by Mukhopadhyay et al. [20], using the
mitochondrial superoxide-speciﬁc indicator MitoSOX™. Brieﬂy, cells
at 80% conﬂuence were treated (or not) with mitochondrial inhibitors
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treated for 30 min at 37 °C with 1 ml of 5 μM MitoSOX™ Red
(Invitrogen) in Opti-MEMmedium. Cells were washed twice with PBS
warmed to 37 °C, then resuspended in 600 μl PBS and analysed
immediately by ﬂow cytometry (FACSAria, BD Biosciences) [20].
3. Results
3.1. The human MRPS12/SARSM bidirectional promoter depends on a
similar CCAAT box array as in mouse
The human bidirectional MRPS12/SARSM promoter contains an
array of four CCAAT box elements (Fig. 1), with the same orientation,
and approximately the same positions, as in the homologous mouse
promoter, where theywere previously shown to govern the activity and
directionality of the transcription [7]. To identify elements in the
human promoter required for transcription, we used a similar dual
reporter strategy as in mouse, combined with deletions and point
mutations destroying each CCAAT box in turn. The various constructs
were tested by transient transfection into HEK293T cells. Deletion
analysis (Fig. 2A) identiﬁed the 200 bp containing the CCAAT box array
as being essential for transcription. A deletion of just the SARSM 5′ utr
(construct HF2) abolished transcription in the SARSM direction, but this
was restored at an increased level by concomitant deletion of CCAAT
box I (HF3), whichwe infer to act as a repressor element for SARSM as in
mouse (i.e. directing transcription in the opposing direction). The
construct retaining only the region of CCAAT boxes III and IV (HF4) was
able to sustain amoderate level of transcription, but CCAAT box IV alone
(HF5) appeared to confer very little transcriptional activity, and
deletions further downstream (HF6, HF7) gave no transcription.
Deleting from the opposite side, i.e. in the MRPS12 5′ utr (RF2) and
ﬁrst intron (RF3, RF4), revealed evidence for negatively acting elements,
as in mouse. However, unlike the case of mouse, their elimination
boosted transcription only in the SARSM direction, and actually
decreased it in the MRPS12 direction. Removal of the entire ﬁrst intron
of MRPS12 (RF5) restored transcription in the SARSM direction to
control levels, but transcription in theMRPS12 direction remained low.Fig. 1. Molecular architecture of the Mrps12-Sarsm bidirectional promoter region in human
Numbering commences at the nucleotide pair immediately 5′ to the Sarsm start codon. Based o
Mrps12mRNAhas at least twomajor splice variants as shown,with different transcription startsDestruction of the CCAAT boxes by point mutations (CCAAT→CGTAT)
gaveavery similar result as inmouse (Fig. 2B). EliminationofCCAATboxes
II or III had very little effect, but CCAAT boxes I and IVwere each required
for enforcing directionality: elimination of CCAAT box I boosted
transcription in the SARSM direction, with a negative effect on transcrip-
tion in the opposite direction, whereas elimination of CCAAT box IV
boosted transcription in the MRPS12 direction, with a small negative
effect in the opposite direction. Destruction of the NRF-2 consensus
binding site produced no signiﬁcant effect on transcription (Fig. 2B).
EMSA using overlapping fragments from the promoter and MRPS12
ﬁrst intron (Fig. 3) identiﬁed a complexwhichwas formed by fragments
containing the CCAAT boxes. A ten-foldmass excess of other CCAAT box-
containing fragments competed efﬁciently, except for a fragments
containing only CCAAT box III, which was a comparatively poor
competitor. An antibody against NF-Y supershifted the CCAAT box-
containing complexes, but antibodies against C/EBP (or c-Jun, not
shown) failed to bring about a convincing supershift. A probe fragment
spanning theMRPS12 5′ utr and ﬁrst intron gave no EMSA signal.
3.2. Mitochondrial stresses induce a biphasic response in the
Mrps12/Sarsm promoter in mouse cells
CCAAT box elements and the factor NF-Ywhich interacts with them
are generally considered to be components of a ‘global’ transcription
machinery linked to cell proliferation. To address the issue of how a
bidirectional promoter governed by these elements responds to
mitochondrial OXPHOS stress, we treated cells with a variety of drugs
actingdirectly or indirectly onOXPHOS, then transfected themwith the
bidirectional reporter constructs used previously. We then measured
reporter expression after 24 h, alongside that in cells not treated with
drugs (Figs. 4, 5). Treatment of mouse 3T3 cells (Fig. 4A) with OXPHOS
inhibitors (antimycin plus rotenone), or with the uncoupler FCCP,
produced large and comparable increases in promoter activity in both
directions (3–7-fold). Inhibitors of mitochondrial protein synthesis,
such as doxycycline or thiamphenicol, produced much more modest
stimulation of promoter activity (1.2–1.5-fold, in several cases barely
signiﬁcant). When the same drugs were added back 4 h followingand mouse. For complete sequence of the human promoter see Supplementary Figure 1.
n EST data, mouse and human Sarsm (SARSM) mRNAs each exist in a single isoform.Mouse
. In human,MRPS12mRNAhas a single transcription start site but again two splice variants.
Fig. 2. Reporter analysis of the humanMRPS12/SARSM bidirectional promoter in HEK293 cells. The promoter region (from nucleotide 1 to 557 as numbered in Supplementary Fig.1, i.e.
immediately ﬂanked by the two start codons) was cloned into the NcoI site of the customized vector pFRL [7]. (A) A set of deletions was also created, as shown. In all constructs shown,
transcription in the SARSM direction was assayed as ﬁreﬂy luciferase activity, and in theMRPS12 direction as Renilla luciferase activity. The main features of the promoter region are
reproduced from Fig. 1, and the deleted segment in each construct is indicated as a dotted line (see Supplementary Table 1 for details). (B) Point mutations in which each of the four
CCAAT boxes (open circles) or the NRF-2 consensus binding sequence (ﬁlled diamond) was individually destroyed were also tested, as shown. Expression in the two directions was
calculated based on luciferase activities after transfection, as follows. First, activities were normalized to that of β-galactosidase in the same extracts, to correct for transfection
efﬁciency. Expressionwas then normalized against that supported by thewild-type promoter in the same direction (=100 arbitrary units, a.u.), whichwasmeasured afresh in every set
of experiments. Plotted data are means±SD from at least three independent transfections. Background luciferase activities of the empty pFRL vector, compared with the wild-type
promoter, were 0.2% (Renilla) and 1.5% (ﬁreﬂy). As in mouse, transcriptional activity in the MRPS12 direction was approximately 3.4 times that in the SARSM direction, based on
comparing the mean activities of the wild-type reporter construct cloned in the two opposite directions.
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resulted (Fig. 4B), with promoter activity in both directions greatly
diminished by FCCP (to 20–30% of that untreated cells), and more
modestly downregulated by the other drugs. Pre-treatment with
arginine and/or citrulline at various concentrations, in order to
stimulate NO production [21], or with CoCl2 to induce hypoxia [22],
produced only very small changes in promoter activity (≤20% and
generally not signiﬁcant, data not shown). In mouse C2C12 myoblasts,
pre-treatmentwith the samedrugs produced only the downregulation
seen in 3T3 cells under more prolonged exposure (Fig. 4C). Down-
regulation was seen even at very low drug concentrations. In all cases
the effects on transcription in the two directionswere comparable. Theupregulationseen followingdrug treatment in3T3cellsmightbepartly
a response to the removal of stress.However, prolonged treatmentwith
FCCP at a very low drug concentration also produced upregulation,
albeit much more modest, (Supplementary Fig. 2), indicating that the
stress itself may be the primary inducer of the response.
3.3. Mitochondrial stresses induce a more weakly biphasic response in
the MRPS12/SARSM promoter in human cells
The apparently biphasic and cell type-speciﬁc responses of the
mouse promoter undermitochondrial stress prompted the question of
how the human promoter responds to similar stresses in different
Fig. 3. EMSA and ChIP analysis of protein-binding to the human bidirectional promoter region. The main features of the promoter region (top left) are reproduced from Fig. 1, aligned
with the nine fragments tested in the assays, denoted a through i. EMSA gels for probes a and b are shown. Reactions contained a 10-fold molar excess of competitor fragments as
indicated. Supershift experiments used antibodies against NF-Y (Y) and C/EBP (C). An antibody against C-Junwas tested in separate supershift experiment (not shown) and found to be
negative. The arrow indicates the major protein–DNA complex inferred to represent binding at the CCAAT boxes. The double-headed arrow denotes the complex supershifted by the
antibody against NF-Y. ChIP assay (top-right) conﬁrms binding of NF-Y in vivo, since the promoter was efﬁciently immunoprecipitated by anti-NF-Y antibody but not by an anti-FLAG
monoclonal.
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carcinoma) and U2OS (osteosarcoma) cells under similar conditions as
the initial trials in mouse cells (12 h pre-treatment with various drug
concentrations). HEK293 and U2OS cells behaved essentially the same
as each other and asmouse C2C12myoblasts: promoter activity in both
directions was downregulated by all drugs tested, and even at low
concentrations (Fig. 5A, B). Under prolonged drug exposure, such as
was able to reverse the pattern of stimulation in mouse 3T3 cells,
HEK293 cells showed almost identical responses as in the case of pre-
treatment alone (data not shown). In HeLa cells (Fig. 5C) the pattern
was qualitatively more similar to that seen in 3T3 cells, although
quantitatively less dramatic. At low concentrations of all the drugs
tested therewas a consistent but verymodest stimulation of promoter
activity in both directions (typically 1.3 to 1.5-fold), whereas at higher
drug concentrations there was generally little effect, or even a slight
inhibition. Doxycycline at high concentration (0.5 mM) produced the
strongest stimulation (2-fold), althoughmuch lower doses still elicited
a stimulatory effect. To evaluate whether the different responses of
human and mouse cells reﬂected differences in the intracellular
signalling machinery or in the nature of the promoters from the two
species, we tested the mouse reporter construct in HEK293 cells and
the human reporter construct in 3T3 cells (data summarized in Table 1,
see also Supplementary Fig. 3). In HEK293 cells the mouse reporter
construct behaved similarly to the humanpromoter (i.e. showed dose-
dependent downregulation), although the effects on transcription in
the Mrps12 direction were somewhat weaker than in the Sarsm
direction, and the responses to some drugs appeared to saturate, i.e.
low and high doses gave more similar effects than when the human
promoter construct was used. In 3T3 cells the human promotershowed only very weak responses to mitochondrial OXPHOS stress,
regardless of the drug concentrations used.
3.4. Involvement of different transcription factors in regulation of the
Mrps12/Sarsm promoter by mitochondrial stress
The strong stimulation of Mrps12/Sarsm promoter activity in 3T3
cells subjected to mitochondrial OXPHOS stress raises the issue of
which elements of the promoter confer this responsiveness, andwhich
transcription factors are involved. We tested for possible involvement
of the CCAAT box array and other putative transcription-factor binding
sites by using variants of the bidirectional reporter construct carrying
point mutations which destroy these various sites (Fig. 6A). The
elimination of all 4 CCAAT boxes, even though it caused greatly
reduced transcription in both directions and shifted the balance of
residual transcription in the Sarsm direction, as shown previously, did
not signiﬁcantly affect the proportionate amount of induction by FCCP.
Removal of the NRF-2 binding site or of the two AP-1 consensus
sequences in the bidirectional promoter also did not affect induction
by FCCP. Of the other putative binding sites tested, none caused a
substantial reduction in the proportionate induction by FCCP when
eliminated, with the arguable exception of the putative binding site for
MYB, which overlaps CCAAT box III, destruction of which caused a 40%
reduction in transcriptional induction by FCCP in theMrps12 direction.
In contrast, we saw a clear mitigation of the downregulation of the
promoter brought about by prolonged drug exposure, when the 4
CCAAT boxes were destroyed (Fig. 6B). Expression in the Mrps12
direction remained at approximately the same level as in untreated
cells, and the sharp drop in expression in the Sarsm direction brought
Fig. 4. Effects of mitochondrial OXPHOS stress on transcriptional activity of the mouse Mrps12/Sarsm promoter. Cells as indicated were pre-treated with various drugs to inhibit
mitochondrial OXPHOS or protein synthesis. In part (B) 3T3 cells were also treated with the drugs after transfection (see Materials and methods). All experiments used the wild-type
dual reporter construct in which transcription in the Sarsm direction was assayed as ﬁreﬂy luciferase activity, and in the Mrps12 direction as Renilla luciferase activity. In each case,
luciferase activities were ﬁrst normalized to that of β-galactosidase in the same extracts, to correct for transfection efﬁciency. Expressionwas then normalized against that supported
by the wild-type promoter in the same direction, in untreated cells (taken as 100%, dotted vertical lines). Plotted data (black bars in the Mrps12 direction, white bars in the Sarsm
direction) are means±SD from at least three independent transfections of drug-treated cells.
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Table 1













FCCP ↓↓ ↓↓ (↓) at high dose ↑↑
Antimycin+
rotenone
↓↓ ↓ (↓) at high dose ↑↑
Doxycycline ↓↓ ↓ − ↑







No signiﬁcant change −.
For full data see Figs. 4, 5 and Supplementary Fig. 3.
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wild-type construct. Elimination of the NRF-2 binding consensus had a
slight mitigating effect, whereas abolition of both copies of the AP-1
consensus had none.
3.5. ROS production correlates with the induction of Mrps12/Sarsm
promoter activity by mitochondrial stress
To investigate possible components of the inducing signal, we
treated 3T3 cells with the same drugs that gave induction to
varying degrees, then quantiﬁed mitochondrial ROS (superoxide)
production using MitoSOX™ ﬂuorescence (Fig. 7). The potency of
different drugs in producing the transcriptional response was well
correlated with the amount of ROS production (FCCPNantimycin+
rotenoneNdoxycycline∼ thiamphenicol). In HEK293 cells, the drugs
produced similar effects on ROS production, even though the
effects on transcription were opposite.
4. Discussion
In previous work [7] we found that the mouse Mrps12/Sarsm
promoter is governed by an array of 4 CCAAT boxes, interacting with
the factor NF-Y to maintain bidirectional transcription in proliferating
cells. In the present work we present evidence, using a similar reporter
strategy and EMSA, that the human MRPS12/SARSM promoter is
regulated in an essentially similar manner in growing cells. In response
to agents that inhibit mitochondrial OXPHOS or biogenesis of the
OXPHOS system, we found that transcription from both the mouse and
human promoter is modulated in a cell type-speciﬁc fashion. In
particular, expression of both Sarsm andMrps12 was stimulated in 3T3
ﬁbroblasts, whereas an equivalent treatment of C2C12 myoblasts or
more prolonged drug treatment of 3T3 cells resulted in an opposite
effect (dose-dependent decrease in transcriptional activity). In human
cells, mitochondrial OXPHOS stress produced similarly variable effects
on expression from the bidirectional promoter, acting negatively in
HEK293 and U2OS osteosarcoma cells, or at high doses in HeLa cells, but
with a weakly positive effect in HeLa cells at low dosage. Reciprocal
experiments in which each promoter was tested in cells of the other
species suggested that downregulation in response to mitochondrial
OXPHOS stress was an inherent property of some cell types, whereas
activation responses required species-speciﬁc factors or promoter
elements. We investigated the nature of these response elements
using amutational approach in 3T3 cells treatedwith FCCP. This showedFig. 5. Effects of mitochondrial OXPHOS stress on transcriptional activity of the human MRP
mitochondrial OXPHOS or protein synthesis. All experiments used the wild-type dual rep
luciferase activity, and in theMRPS12 direction as Renilla luciferase activity. In each case, luci
correct for transfection efﬁciency. Expressionwas then normalized against that supported by
vertical lines). Plotted data (black bars in theMRPS12 direction, white bars in the SARSM directhat the inductionof transcription in response tomitochondrialOXPHOS
stress was independent of the CCAAT box array, of the NRF-2 element,
and of a set of other putative binding sites for transcription factors.
Conversely, the CCAAT box array was shown to be important for
transcriptional downregulation under more prolonged mitochondrial
stress.Wenowdiscuss, brieﬂy, someof the issues arising fromthis study.
4.1. Phylogenetic conservation of the CCAAT box array
Wenotedpreviously [7] that the CCAATboxes, their orientation and
their approximate locations were conserved between human and
mouse. In the present work we provide evidence that the array
functions similarly in the two species. As in mouse, deletion and point
mutation analysis (Fig. 2) indicated the two terminal elements of the
human CCAAT box array to be crucial for enforcing directionality
towards the opposite end of the promoter, i.e. CCAAT box I, nearest to
SARSM, favours transcription towardsMRPS12whilst suppressing that
towards SARSM, whereas CCAAT box IV at the other end of the array
functions in the reciprocal manner. Mutation of either of the
intermediate CCAAT boxes II or III did not affect the directionality of
transcription, suggesting that, as in mouse, these play an accessory
role. Based on EMSA (Fig. 3), the same transcription factor interacts
with all four boxes, and supershifting identiﬁed it as NF-Y. In themouse
study, we found weak evidence for C/EBP also interacting with the
array, at least in some cell types, although NF-Y binding in vivo was
conﬁrmed by chromatin immunoprecipitation. Although the study of
the human promoter is less extensive than the one carried out in
mouse, it provides evidence that the CCAAT box array functions in an
analogous manner, relying on the unusual property of NF-Y to bind
DNA and contact the transcriptional machinery in either orientation.
Bioinformatic analysis has revealed that CCAAT boxes are found
preferentially in bidirectional promoters in the human genome [23],
although the speciﬁc presence of NF-Y as the factor involved has not
been tested. Interestingly, the bindingmotif for GABP (NRF-2) was also
preferentially found in bidirectional promoters, whichwere also found
to be enriched in modiﬁed histones and RNA polymerase II occupancy.
This strengthens the view of bidirectional promoters as being
predominantly associated with genes expressed at a high level in
growing cells, including genes whose products are required for
mitochondrial biogenesis as part of a ‘growth regulon’. The NRF-2
element in the Mrps12/Sarsm promoter appears to play an accessory
role to that of NF-Y in maintaining high-level expression in proliferat-
ing cells (in mouse) but apparently no role in human, at least in
HEK293 cells, though it may be redundant with other factors.
4.2. Cell-type differences in transcriptional responses to mitochondrial
OXPHOS stress
The Mrps12/Sarsm promoter is clearly able to respond also to
mitochondrial OXPHOS stress, which can partially over-ride or
synergise with proliferative signals, depending on the cell back-
ground. A positive response to mitochondrial OXPHOS stress can be
rationalized on the grounds that failingmitochondrial ATP production,
respiratory electron ﬂow or protein synthesis should generate a signal
to boost the production of key components of the machinery of
mitochondrial biogenesis, which was indeed the case in 3T3 cells and
to a lesser extent in HeLa cells treated transiently or with low levels of
mitochondrial inhibitors. Conversely, in HEK293, C2C12 or U2OS cells,
mitochondrial OXPHOS stress created a superﬁcially paradoxical
effect, i.e. to further downregulate production of mitochondrial
components. The cells responding in this way do not have anythingS12/SARSM promoter. Cells as indicated were pre-treated with various drugs to inhibit
orter construct in which transcription in the SARSM direction was assayed as ﬁreﬂy
ferase activities were ﬁrst normalized to that of β-galactosidase in the same extracts, to
the wild-type promoter in the same direction, in untreated cells (taken as 100%, dotted
tion) are means±SD from at least three independent transfections of drug-treated cells.
Fig. 6. Effects of mutating the mouse Mrps12/Sarsm promoter on transcriptional response to mitochondrial OXPHOS stress. The various dual reporter constructs, shown
diagrammatically at left using the same nomenclature as in Fig. 1, with crosses denoting the sites of the additional mutations as described previously [7], were tested for promoter
activity in 3T3 cells. (A) Cells pre-treatedwith FCCP (15 or 30 μM,which gave statistically indistinguishable results and are therefore pooled). The proportionate amount of induction of
reporter activity by FCCP, typically 2–3-fold, varied, however, in individual experiments, which is assumed to be due to minor differences in the growth state of the cells. Data are
therefore plotted for each mutant construct relative to the induction of the wild-type construct assayed in parallel in the same experiments. Plotted data (black bars in the Mrps12
direction, white bars in the Sarsm direction) are means±SD of the relative induction factor (%) for each construct, i.e. relative to the wild-type construct transfected and induced in
parallel in at least six independent transfections in at least two replicate experiments. (B) Cells pre-treated with 15 μM FCCP, or with 5 μM antimycin plus 2.5 μM rotenone, then re-
exposed to drug(s) 4 h after transfection. Plotted data (black or cross-hatched bars in theMrps12 direction, white or grey bars in the Sarsm direction) are means±SD of the expression
(%) of each construct, relative to that in nondrug-treated cells.
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ders. However, the fact that higher doses of mitochondrial inhibitors
(in HeLa cells) or more prolonged exposure (in 3T3 cells) could shift
the response, indicates that it is ﬁnely poised, and that perhaps all
cells have the capacity to respond in either way given appropriate
conditions.We can suggest three parameters that may play a role. Firstly, the
dependence of a given cell type upon mitochondrial ATP production
for growth may inﬂuence its handling of OXPHOS stresses. In a cell
which is highly dependent on OXPHOS for growth, mitochondrial
stress may simply generate an anti-proliferative signal, which down-
regulates not only genes such as Mrps12 and Sarsm, but the entire
Fig. 7. Effects of different drugs, as indicated, on MitoSOX™ ﬂuorescence of 3T3 and HEK293 cells. Cells were incubated in the drugs for the same times as used in pre-treatment for
transcription assays. Means±SD of three independent experiments.
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exposing them to the risk of apoptosis if external proliferative signals
continue to contradict the cell's internal signals. However, any such
difference is not reﬂected simply by the ease with which cells may be
induced to lose their mtDNA in culture. HeLa cells can be readily
converted to rho-zero status by ethidium bromide treatment [24], and
both 3T3 and C2C12 rho-zero cells have been generated by treatment
with ditercalinium [25]. HEK293 cells are resistant to the effects of
ethidium bromide, but can be converted to rho-zero cells by expression
of a dominant-negative variant of DNA polymerase gamma [26]. U2OS-
derived cells lackingmtDNA have not, to our knowledge, been reported.
A second parameter which may contribute to the differential
response to mitochondrial OXPHOS stress is the cell's susceptibility to
excess ROS production, generally believed to be a major consequence of
OXPHOS inhibition, but also to be involved in signalling. The transcrip-
tional response of 3T3 cells to different drugs was well correlated with
their effects on mitochondrial ROS (superoxide) production, as mea-
suredbyMitoSOX™ﬂuorescence (Fig. 7). However, thedrugshad similar
effects on ROS production in HEK293 cells, which showed an opposite
transcriptional response. Note that the more potent ROS inducers
(antimycin plus rotenone, and FCCP) were again the drugs that had the
strongest effects on transcription, this time in the negative direction.
Some cells may be able to respond to increased ROS production simply
by increasing the mitochondrial OXPHOS capacity, whereas other cell
types, or cells subjected to prolonged or high-level stress, may be
overwhelmed by the damaging effects of excess ROS and implement a
‘last-ditch’ strategy to overcome it by downregulating genes required for
OXPHOS, the source of the excess ROS. Clearly, it would be interesting to
knowwhether generation of ROS species other than superoxide has the
same pattern of correlation with promoter activity.
A third possibility is that the cell line-dependent modulation of
promoter activity in response to mitochondrial stress could partially
reﬂect the different sensitivity of the cell lines to extra-mitochondrial
effects of the drugs. For example, micromolar concentrations of
rotenone are known in some cases [27,28] to induce secondary effects
on cell division by interfering with the microtubular network and
promoting cell death. However, this is unlikely to be the sole para-
meter inﬂuencing the outcome, since the transcriptional responses of
the various cell lines were not well correlated with the amount of
apparent cell death. HeLa cells and C2C12 cells showed no evidence of
cell death when treated with the mitochondrial inhibitors at the
concentrations used, whereas in the HEK293 cultures the same
treatments gave many detached cells.
4.3. Transcription factors involved in mediating responses to
mitochondrial OXPHOS stress
The CCAAT box array, which we earlier showed to be crucial for
maintaining efﬁcient bidirectional transcription in proliferating cells,
is not required, at least in 3T3 cells, for the increase in Mrps12/Sarsmtranscription under mitochondrial OXPHOS stress. The construct
ScatH, in which all four CCAAT boxes are destroyed, showed the
same proportionate induction following FCCP treatment as the wild-
type promoter construct. This negative ﬁnding contrastswith evidence
that NF-Y is involved in mediating the transcriptional response to ER
stress [29–32] and is also implicated in responses to various kinds of
stress that arise during ageing [33]. However, the CCAAT box array
clearly does play a role in mediating the downregulation of the
Mrps12/Sarsm promoter under prolonged OXPHOS stress in 3T3 cells.
This may represent an anti-proliferative mechanism, which gives the
cell time to repair mitochondrial damage before cell division resumes,
and more closely resembles changes that occur during ageing [33].
Downregulation of NF-Ywould be a simplemechanism to decrease the
expression of many genes in the growth regulon under such
conditions, including both Sarsm and Mrps12. Members of the C/EBP
family, including both C/EBPbeta [30] and the C/EBP homologous
protein (CHOP), have been implicated in DNA damage [34] and ER
stress responses [35], and a possible involvement of these factors in the
response to prolonged OXPHOS stress, acting through the Mrps12/
Sarsm CCAAT box array, cannot be ruled out. NRF-2 may play a similar,
albeitminor role in this regard, based on theﬁnding that abolition of its
binding site in the Mrps12/Sarsm promoter also mitigated down-
regulation under prolonged exposure to either FCCP or OXPHOS
inhibitors. Note that, although the CCAAT boxes (and NRF-2 element)
appear to be acting as ‘negative’ regulatory elements in this context,
the effect may be brought about by the destruction or inactivation of
positively acting factors interacting with them, which are essential for
sustaining high-level transcription from the bidirectional promoter.
Mitochondrial OXPHOS stress in a number of cell types appears to
result in an increase in cytosolic calcium [36,37], which has been
postulated as a primary inducer of retrograde signalling [14]. This
involves the activation of speciﬁc transcription factors, including NF-κB,
NFAT and CREBP1 (CREB). The different responses of the various cell
types we tested may therefore reﬂect the presence or activation
potential of theseandother transcription factors, and the responsiveness
thereto of the Mrps12/Sarsm promoter. In the mouse Mrps12/Sarsm
promoterwe identiﬁed previously a number of putative binding sites for
transcription factors, including both CREB and NFAT. These were not
required for promoter activity in proliferating cells [7]. However, we
found no evidence in the present study implicating them in response to
mitochondrial OXPHOS stress in 3T3 cells. Indeed, none of the putative
binding sites for transcription factors that we identiﬁed on the basis of
sequence appeared to be needed for the induction of transcription of
Mrps12/Sarsm in 3T3 cells treated with FCCP, apart from the modest
attenuation of the response when the putative MYB binding site was
destroyed. AlthoughMYB is unlikely to be involved directly, themutated
nucleotide pairs may inﬂuence the binding of another, as yet
unidentiﬁed transcription factor involved in the response.
Recently, theAP-1 component c-Junwas shown to participate in the
mitochondrial response to taxol-induced stress inmelanoma cells [38],
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protein 2). However, in the present study, the abolition of the putative
AP-1 binding sites in the mouse Mrps12/Sarsm promoter affected
neither its upregulation nor downregulation in 3T3 cells in response to
different levels of mitochondrial stress. It remains possible that AP-1 is
only involved in enabling the promoter to respond to more drastic
insults, with apoptosis as a ﬁnal readout. ROS signalling [10], acting via
AP-1, has been implicated in the induction of apoptosis inmuscle from
mitochondrial disease patients [1].
Deletion analysis identiﬁed a region of theMrps12 ﬁrst intron, both
in mouse [7] and in human (this study), which contains one or more
negatively acting transcription-regulatory elements. It is possible that
these are somehow involved in promoter activation under conditions
of OXPHOS stress in some cell types, but further work will be required
to localize these elements, identify the proteins with which they
interact and deﬁne their physiological roles. Since the human
promoter did not function in 3T3 cells in an identical manner as the
mouse promoter, we may infer that some of the transcriptional
machinery involved is incompatible between the species, or else the
responding elements are (partially) located in human elsewhere than
in the core promoter andMRPS12 ﬁrst intron. The only other clue as to
the nature of elementsmediating the response to OXPHOS stress is the
ﬁnding that some nucleotides within the MYB binding site consensus
close to CCAAT box III are in some way involved, although no factor
binding to this region, other than NF-Y, was detected by EMSA. A
saturation mutagenesis is likely to be needed to deﬁne fully the
responding elements in the DNA and characterize the components of
the transcriptional machinery with which they interact.
Acknowledgements
This work was supported by funding from the Academy of Finland,
Tampere University Hospital and the Juselius Foundation. We thank
Anu Suomalainen for advice on hypoxia, Eric Dufour for advice
and assistance with MitoSOX™ ﬂuorescence measurements, Bettina
Lindroos for help with ﬂow cytometry and Merja Jokela, Outi
Kurronen and Tea Tuomela for technical assistance.
Appendix A. Supplementary data
Supplementary data associatedwith this article can be found, in the
online version, at doi:10.1016/j.bbamcr.2008.08.001.
References
[1] M. Filosto, P. Tonin, G. Vattemi, C. Savio, N. Rizzuto, G. Tomelleri, Transcription factors
c-Jun/activator protein-1 and nuclear factor-kappa B in oxidative stress response in
mitochondrial diseases, Neuropathol. Appl. Neurobiol. 29 (2003) 52–59.
[2] Y. Xia, L.M. Buja, J.B. McMillin, Activation of the cytochrome c gene by electrical
stimulation in neonatal rat cardiac myocytes. Role of NRF-1 and c-Jun, J. Biol.
Chem. 273 (1998) 12593–12598.
[3] A. Franko, S. Mayer, G. Thiel, L. Mercy, T. Arnould, H.T. Hornig-Do, R.J. Wiesner,
S. Goffart, CREB-1alpha is recruited to and mediates upregulation of the cyto-
chrome c promoter during enhanced mitochondrial biogenesis accompanying
skeletal muscle differentiation, Mol. Cell Biol. 28 (2008) 2446–2459.
[4] V.K. Mootha, C. Handschin, D. Arlow, X. Xie, J. St Pierre, S. Sihag, W. Yang,
D. Altshuler, P. Puigserver, N. Patterson, P.J. Willy, I.G. Schulman, R.A.
Heyman, E.S. Lander, B.M. Spiegelman, Erralpha and Gabpa/b specify PGC-
1alpha-dependent oxidative phosphorylation gene expression that is altered
in diabetic muscle, Proc. Natl. Acad. Sci. USA 101 (2004) 6570–6575.
[5] L. Gopalakrishnan, R.C. Scarpulla, Differential regulation of respiratory chain
subunits by a CREB-dependent signal transduction pathway, role of cyclic AMP in
cytochrome c and COXIV gene expression, J. Biol. Chem. 269 (1994) 105–113.
[6] S. Scacco, R. Vergari, R.C. Scarpulla, Z. Technikova-Dobrova, A. Sardanelli, R. Lambo,
V. Lorusso, S. Papa, cAMP-dependent phosphorylation of the nuclear encoded 18-
kDa (IP) subunit of respiratory complex I and activation of the complex in serum-
starved mouse ﬁbroblast cultures, J. Biol. Chem. 275 (2000) 17578–17582.
[7] E. Zanotto, Z.H. Shah, H.T. Jacobs, The bidirectional promoter of two genes for the
mitochondrial translational apparatus inmouse is regulated byan array of CCAATboxes
interacting with the transcription factor NF-Y, Nucleic Acids Res. 35 (2007) 664–677.
[8] R.C. Scarpulla, Nuclear control of respiratory gene expression in mammalian cells,
J. Cell. Biochem. 97 (2006) 673–683.[9] F. Fontanesi, C. Jin, A. Tzagoloff, A. Barrientos, Transcriptional activators HAP/NF-Y
rescue a cytochrome c oxidase defect in yeast and human cells, Hum. Mol. Genet.
17 (2008) 775–788.
[10] Q. Felty, W.C. Xiong, D. Sun, S. Sarkar, K.P. Singh, J. Parkash, D. Roy, Estrogen-
induced mitochondrial reactive oxygen species as signal-transducing messengers,
Biochemistry 44 (2005) 6900–6909.
[11] Z. Liu, R.A. Butow, Mitochondrial retrograde signaling, Annu. Rev. Genet. 40 (2006)
159–185.
[12] S.G. Dann, G. Thomas, The amino acid sensitive TOR pathway from yeast to
mammals, FEBS Lett. 580 (2006) 2821–2829.
[13] R.A. Butow, N.G. Avadhani. Mitochondrial signaling: the retrograde response, Mol.
Cell 14 (2004) 1–15.
[14] G. Biswas, O.A. Adebanjo, B.D. Freedman, H.K. Anandatheerthavarada, C.
Vijayasarathy, M. Zaidi, M. Kotlikoff, N.G. Avadhani, Retrograde Ca2+ signaling in
C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic
stress: a novel mode of inter-organelle crosstalk, EMBO J. 18 (1999) 522–533.
[15] G. Biswas, M. Guha, N.G. Avadhani, Mitochondria-to-nucleus stress signaling in
mammalian cells: nature of nuclear gene targets, transcription regulation, and
induced resistance to apoptosis, Gene 354 (2005) 132–139.
[16] T.Arnould, S. Vankoningsloo, P. Renard,A.Houbion,N.Ninane,C.Demazy, J. Remacle, M.
Raes, CREB activation induced by mitochondrial dysfunction is a new signaling
pathway that impairs cell proliferation, EMBO J. 21 (2002) 53–63.
[17] L.G. Nijtmans, P. Klement, J. Houstek, C. van den Bogert, Assembly ofmitochondrial
ATP synthase in cultured human cells: implications for mitochondrial disease,
Biochim. Biophys. Acta. 1272 (1995) 190–198.
[18] A.M. Kroon, Protein synthesis in mitochondria. 3. On the effects of inhibitors on
the incorporation of amino acids into protein by intact mitochondria and digitonin
fractions, Biochim. Biophys. Acta 108 (1965) 275–284.
[19] S. Kuzela, A. Mutvei, B.D. Nelson, Inhibition of mitochondrial protein synthesis in
regenerating rat liver stimulates mitochondrial transcription, Biochim. Biophys.
Acta 936 (1988) 372–376.
[20] P. Mukhopadhyay, M. Rajesh, K. Yoshihiro, G. Haskó, P. Pacher, Simple quantitative
detection of mitochondrial superoxide production in live cells, Biochem. Biophys.
Res. Commun. 358 (2007) 203–208.
[21] G. Wu, S.M. Morris, Arginine metabolism: nitric oxide and beyond, Biochem J. 336
(1998) 1–17.
[22] G. Wang, T.K. Hazra, S. Mitra, H.M. Lee, E.W. Englander, Mitochondrial DNA
damage and a hypoxic response are induced by CoCl2 in rat neuronal PC12 cells,
Nucleic Acids Res. 28 (2000) 2135–2140.
[23] J.M. Lin, P.J. Collins, N.D. Trinklein, Y. Fu, H. Xi, R.M. Myers, Z. Weng, Transcription
factor binding and modiﬁed histones in human bidirectional promoters, Genome
Res. 17 (2007) 818–827.
[24] J. Hayashi, S. Ohta, A. Kikuchi, M. Takemitsu, Y. Goto, I. Nonaka, Introduction of
disease-related mitochondrial DNA deletions into HeLa cells lacking mitochon-
drial DNA results in mitochondrial dysfunction, Proc. Natl. Acad. Sci. USA, 88
(1991) 10614–10618.
[25] K. Inoue, S. Ito, D. Takai, A. Soejima, H. Shisa, J.B. LePecq, E. Segal-Bendirdjian,
Y. Kagawa, J.I. Hayashi, Isolation of mitochondrial DNA-less mouse cell lines
and their application for trapping mouse synaptosomal mitochondrial DNA
with deletion mutations, J. Biol. Chem. 272 (1997) 15510–15515.
[26] M. Jazayeri, A. Andreyev, Y. Will, M. Ward, C.M. Anderson, W. Clevenger, Inducible
expression of a dominant negative DNA polymerase-gamma depletes mitochon-
drial DNA and produces a rho0 phenotype, J. Biol. Chem. 278 (2003) 9823–9830.
[27] L.E. Marshall, R.H. Hime, Rotenone inhibition of tubulin self-assembly, Biochim
Biophys Acta. 543 (1978) 590–594.
[28] P. Srivastava, D. Panda, Rotenone inhibits mammalian cell proliferation by inhibiting
microtubule assembly through tubulin binding, FEBS J. 274 (2007) 4788–4801.
[29] R. Luo, J.F. Lu, Q. Hu, S.N. Maity, CBF/NF-Y controls endoplasmic reticulum stress
induced transcription through recruitment of both ATF6(N) and TBP, J. Cell.
Biochem. (2008) Mar 17 [Epub ahead of print].
[30] G. Donati, C. Imbriano, R. Mantovani, Dynamic recruitment of transcription factors
and epigenetic changes on the ER stress response gene promoters, Nucleic Acids
Res. 34 (2006) 3116–3127.
[31] M. Abdelrahim, S. Liu, S. Safe, Induction of endoplasmic reticulum-induced stress
genes in Panc-1 pancreatic cancer cells is dependent on Sp proteins, J. Biol. Chem.
280 (2005) 16508–16513.
[32] H. Yoshida, T. Okada, K. Haze, H. Yanagi, T. Yura, M. Negishi, K. Mori, Endoplasmic
reticulum stress-induced formation of transcription factor complex ERSF includ-
ing NF-Y (CBF) and activating transcription factors 6alpha and 6beta that activates
the mammalian unfolded protein response, Mol. Cell Biol. 21 (2001) 1239–1248.
[33] K. Matuoka, K.Y. Chen, Transcriptional regulation of cellular ageing by the CCAAT
box-binding factor CBF/NF-Y, Ageing Res. Rev. 1 (2002) 639–651.
[34] A.J. Fornace, D.W. Nebert, M.C. Hollander, J.D. Luethy, F. Papathanasiou, J. Fargnoli,
N.J. Holbrook, Mammalian genes coordinately regulated by growth arrest signals
and DNA-damaging agents, Mol. Cell. Biol. 9 (1989) 4196–4203.
[35] H. Zinszner, M. Kuroda, X. Wang, N. Batchvarova, R.T. Lightfoot, H. Remotti, J.L.
Stevens, D. Ron, CHOP is implicated in programmed cell death in response to
impaired function of the endoplasmic reticulum, Genes Develop.12 (1998) 982–995.
[36] D.F. Babcock, J. Herrington, P.C. Goodwin, Y.B. Park, B. Hille, Mitochondrial
participation in the intracellular Ca2+ network, J. Cell Biol. 136 (1997) 833–844.
[37] Y. Lou, J. Bond, V.M. Ingram, Compromised mitochondrial functions leads to
increased cytosolic calcium and activation of MAP kinases, Proc. Natl Acad. Sci.
USA 94 (1997) 9705–9710.
[38] D. Selimovic, M. Hassan, Y. Haikel, U.R. Hengge, Taxol-induced mitochondrial
stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase
(JNK) and p38 pathways via uncoupling protein 2, Cell Signal. 20 (2008) 311–322.
